用于治疗视网膜疾病的生物类似药。 - Suppr

Suppr

超能文献

Biosimilars for the Treatment of Retinal Diseases.

作者信息

Narayanan Raja, Hariprasad Seenu M, Sheth Jay

出版信息

Ophthalmic Surg Lasers Imaging Retina. 2021 May;52(5):242-246. doi: 10.3928/23258160-20210429-01. Epub 2021 May 1.

DOI:10.3928/23258160-20210429-01

PMID:34044720

Abstract

摘要

相似文献

Ophthalmic Surg Lasers Imaging Retina. 2021 May;52(5):242-246. doi: 10.3928/23258160-20210429-01. Epub 2021 May 1.

Coming of Age: Biosimilars.

Ophthalmic Surg Lasers Imaging Retina. 2018 Mar 1;49(3):162-165. doi: 10.3928/23258160-20180221-02.

Am J Ophthalmol. 2021 Apr;224:36-42. doi: 10.1016/j.ajo.2020.11.017. Epub 2020 Dec 9.

Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns.评论：印度视网膜疾病生物类似药的使用：挑战与担忧

Indian J Ophthalmol. 2021 Feb;69(2):357-358. doi: 10.4103/ijo.IJO_39_21.

Ophthalmology. 2022 Jan;129(1):65-66. doi: 10.1016/j.ophtha.2021.09.008. Epub 2021 Sep 15.

Int Ophthalmol Clin. 2024 Jan 1;64(1):129-139. doi: 10.1097/IIO.0000000000000509. Epub 2023 Dec 26.

Razumab -- the role of biosimilars for the treatment of retinal diseases.雷珠单抗——生物类似药在视网膜疾病治疗中的作用。

Drugs Today (Barc). 2021 Aug;57(8):499-505. doi: 10.1358/dot.2021.57.8.3284618.

Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.抗血管内皮生长因子（anti-VEGF）生物类似药使用变化趋势：来自印度玻璃体视网膜学会抗 VEGF 生物类似药调查的见解。

Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.

Best Pract Res Clin Gastroenterol. 2018 Feb-Apr;32-33:35-42. doi: 10.1016/j.bpg.2018.05.003. Epub 2018 May 26.

Who is afraid of biosimilars? Openness to biosimilars in an Australian cohort of patients with rheumatoid arthritis.谁害怕生物类似药？澳大利亚类风湿关节炎患者对生物类似药的态度。

Intern Med J. 2020 Mar;50(3):374-377. doi: 10.1111/imj.14753.

引用本文的文献

Quantitative Assessment of En‑face OCT‑Derived Minimum Intensity Fluid Changes Following Ranibizumab Biosimilar Therapy in Macular Neovascularization Secondary to nAMD and PCV.雷珠单抗生物类似药治疗继发于湿性年龄相关性黄斑变性（nAMD）和息肉状脉络膜血管病变（PCV）的黄斑新生血管后，基于频域光学相干断层扫描（En-face OCT）的最小强度液体变化的定量评估

Clin Ophthalmol. 2025 Jul 29;19:2505-2512. doi: 10.2147/OPTH.S542496. eCollection 2025.

Clinical and Socioeconomic Burden of Retinal Diseases: Can Biosimilars Add Value? A Narrative Review.视网膜疾病的临床与社会经济负担：生物类似药能否增添价值？一篇叙述性综述。

Ophthalmol Ther. 2025 Apr;14(4):621-641. doi: 10.1007/s40123-025-01104-3. Epub 2025 Feb 26.

Efficacy and Safety of an Indian Bevacizumab BIOSimilar (BEVATAS) for Retinal Vein Occlusion (BIOS-RVO Study).一种印度贝伐单抗生物类似药（BEVATAS）用于视网膜静脉阻塞的疗效和安全性（BIOS-RVO研究）

Clin Ophthalmol. 2024 Oct 9;18:2865-2871. doi: 10.2147/OPTH.S473329. eCollection 2024.

Efficacy of an Indian Bevacizumab BIOSimilar (BEVATAS) for Type 1 and Aggressive Posterior Retinopathy of Prematurity (BIOS-ROP Study).一种印度贝伐单抗生物类似药（BEVATAS）用于1型及侵袭性早产儿视网膜病变的疗效（BIOS-ROP研究）

Clin Ophthalmol. 2024 Jan 6;18:61-68. doi: 10.2147/OPTH.S443104. eCollection 2024.

Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema.治疗糖尿病性黄斑水肿的当前和新型治疗方法。

Cells. 2022 Jun 17;11(12):1950. doi: 10.3390/cells11121950.

An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review.用于治疗视网膜疾病的生物类似药介绍：一篇叙述性综述

Ophthalmol Ther. 2022 Jun;11(3):959-982. doi: 10.1007/s40123-022-00488-w. Epub 2022 Mar 12.

Future of anti-VEGF: biosimilars and biobetters.抗血管内皮生长因子药物的未来：生物仿制药和生物改良药。

Int J Retina Vitreous. 2022 Jan 4;8(1):2. doi: 10.1186/s40942-021-00343-3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验